Want to see HK:2269 full AI Analyst Report?
Top Page
Wuxi Biologics (Cayman)
(2269)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$50.00
▼(-1.28% Downside)
Action:Reiterated
Date:10/01/26
The score is driven mainly by strong financial quality (healthy margins and low leverage) and positive technical trend/momentum. These positives are tempered by a high valuation (P/E ~39.6), slowed recent revenue growth, and cash conversion that remains weaker than reported earnings.
Positive Factors
Strong Profitability
Healthy gross, EBIT, and net margins indicate that the CDMO model is generating substantial value from its services. Improvement versus 2024 supports near-term earnings resilience and provides operating resources to invest in capacity, capabilities, and customer programs.
Negative Factors
Slower Recent Growth
The sharp deceleration in recent revenue growth indicates that the earlier expansion pace has moderated. Slower top-line progression can limit operating leverage, reduce room for rapid capacity utilization gains, and make sustained earnings growth more dependent on project progression.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Healthy gross, EBIT, and net margins indicate that the CDMO model is generating substantial value from its services. Improvement versus 2024 supports near-term earnings resilience and provides operating resources to invest in capacity, capabilities, and customer programs.
Read all positive factors
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$185.50B
Dividend YieldN/A
Average Volume (3M)32.12M
Price to Earnings (P/E)31.6
Beta (1Y)1.39
Revenue Growth21.93%
EPS Growth21.94%
CountryHK
Employees14,705
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.21
Shares Outstanding4,116,762,000
10 Day Avg. Volume36,308,813
30 Day Avg. Volume32,116,601
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)2.49
Price to Sales (P/S)5.41
P/FCF Ratio42.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$58.92Price Target Upside16.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)1.41
Revenue Forecast (FY)HK$25.66B
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Company Description
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufactu...
How the Company Makes Money
Wuxi Biologics makes money primarily by selling fee-based, outsourced R&D and manufacturing services to biopharmaceutical customers developing biologic medicines. Its revenue model is project- and contract-driven across the biologics value chain: ...
Wuxi Biologics (Cayman) Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.62B | 21.79B | 18.68B | 17.03B | 15.27B | 10.29B |
| Gross Profit | 11.21B | 10.02B | 7.65B | 6.83B | 6.72B | 4.83B |
| EBITDA | 9.48B | 8.37B | 6.43B | 5.50B | 6.22B | 4.51B |
| Net Income | 5.01B | 4.91B | 3.36B | 3.40B | 4.42B | 3.39B |
Balance Sheet | ||||||
| Total Assets | 65.35B | 63.72B | 56.98B | 56.58B | 49.56B | 44.03B |
| Cash, Cash Equivalents and Short-Term Investments | 13.04B | 15.74B | 10.71B | 11.24B | 8.71B | 11.13B |
| Total Debt | 2.73B | 3.11B | 4.94B | 4.56B | 4.42B | 4.30B |
| Total Liabilities | 10.80B | 10.66B | 11.50B | 12.56B | 13.35B | 11.33B |
| Stockholders Equity | 48.06B | 47.27B | 41.82B | 40.33B | 35.05B | 32.28B |
Cash Flow | ||||||
| Free Cash Flow | 4.42B | 2.80B | 1.29B | 437.20M | -326.72M | -3.09B |
| Operating Cash Flow | 9.05B | 6.39B | 5.22B | 4.67B | 5.54B | 3.43B |
| Investing Cash Flow | -5.05B | -3.38B | -3.94B | -3.23B | -5.91B | -9.60B |
| Financing Cash Flow | -3.08B | -1.95B | -2.75B | 1.96B | -2.59B | 8.21B |
Wuxi Biologics (Cayman) Technical Analysis
Neutral
50.65
Price Trends
50.48
Negative
43.79
Positive
39.82
Positive
Market Momentum
-1.47
Positive
40.18
Neutral
30.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Neutral. The current price of 50.65 is below the 20-day moving average (MA) of 51.00, above the 50-day MA of 50.48, and above the 200-day MA of 39.82, indicating a neutral trend. The MACD of -1.47 indicates Positive momentum. The RSI at 40.18 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2269.
Wuxi Biologics (Cayman) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$185.50B | 31.62 | 10.51% | ― | 21.93% | 21.94% | |
64 Neutral | HK$85.67B | -16.09 | -16.23% | 0.35% | 53.48% | -120.02% | |
64 Neutral | HK$2.65B | 13.18 | 4.45% | 0.27% | 7.38% | 7.90% | |
63 Neutral | HK$3.04B | 36.52 | 3.02% | ― | 10.32% | 178.23% | |
61 Neutral | HK$18.66B | 41.95 | 15.94% | ― | 48.04% | 166.72% | |
53 Neutral | HK$78.08B | 40.40 | 10.93% | 0.85% | 24.21% | 19.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2269
Wuxi Biologics (Cayman)
45.06
8.48
23.18%
HK:1548
Genscript Biotech
37.70
21.52
133.00%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
26.92
1.78
7.10%
HK:1521
Frontage Holdings Corp.
1.49
0.24
19.20%
HK:1873
Viva Biotech Holdings
1.28
-1.09
-45.97%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
42.00
16.12
62.29%
Wuxi Biologics (Cayman) Corporate Events
WuXi Biologics Schedules Conference Calls to Present 2026 Interim Results
Aug 25, 2026
WuXi Biologics (Cayman) Inc., a Hong Kong-listed provider of contract biologics research and manufacturing services, offers end-to-end solutions to pharmaceutical and biotech clients worldwide. The company operates within the life sciences sector,...
Wuxi Biologics Posts Strong Interim Growth as Integrated Biologics Project Portfolio Expands
Aug 25, 2026
Wuxi Biologics reported unaudited interim results for the six months ended June 30, 2026, showing revenue rising 18.4% year-on-year to RMB 11,787.2 million and gross profit up 28.1%. Net profit grew 5.8% to RMB 2,916.2 million, while adjusted net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.